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ABSTRACT
Background
Leber congenital amaurosis (LCA), a heterogeneous early-onset retinal dystrophy, accounts
for ;15% of inherited congenital blindness. One cause of LCA is loss of the enzyme
lecithin:retinol acyl transferase (LRAT), which is required for regeneration of the visual
photopigment in the retina.
Methods and Findings
An animal model of LCA, the Lrat
 /  mouse, recapitulates clinical features of the human
disease. Here, we report that two interventions—intraocular gene therapy and oral
pharmacologic treatment with novel retinoid compounds—each restore retinal function to
Lrat
 /  mice. Gene therapy using intraocular injection of recombinant adeno-associated virus
carrying the Lrat gene successfully restored electroretinographic responses to ;50% of wild-
type levels (p , 0.05 versus wild-type and knockout controls), and pupillary light responses
(PLRs) of Lrat
 /  mice increased ;2.5 log units (p , 0.05). Pharmacological intervention with
orally administered pro-drugs 9-cis-retinyl acetate and 9-cis-retinyl succinate (which chemically
bypass the LRAT-catalyzed step in chromophore regeneration) also caused long-lasting
restoration of retinal function in LRAT-deficient mice and increased ERG response from ;5% of
wild-type levels in Lrat
 /  mice to ;50% of wild-type levels in treated Lrat
 /  mice (p , 0.05
versus wild-type and knockout controls). The interventions produced markedly increased levels
of visual pigment from undetectable levels to 600 pmoles per eye in retinoid treated mice, and
;1,000-fold improvements in PLR and electroretinogram sensitivity. The techniques were
complementary when combined.
Conclusion
Intraocular gene therapy and pharmacologic bypass provide highly effective and
complementary means for restoring retinal function in this animal model of human hereditary
blindness. These complementary methods offer hope of developing treatment to restore vision
in humans with certain forms of hereditary congenital blindness.
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Development of successful treatments for inherited and
acquired retinal disease caused by gene mutations represents
a major challenge [1]. Recessive congenital defects arising
from gene inactivation and subsequent disruption of a
metabolic pathway are particularly amenable to pharmaco-
logical treatment or somatic gene therapy. Oral administra-
tion of appropriate compounds can correct visual deﬁcits in
humans and other animals by bypassing a block in the
retinoid cycle [2]. Sorsby’s fundus dystrophy and Leber
congenital amaurosis (LCA) are two examples. Sorsby’s
fundus dystrophy, an autosomal-dominant retinal degener-
ation caused by mutations in the tissue inhibitor of the
metalloproteinases-3 gene, leads to night blindness [1]. Vitamin
A (retinol [ROL]) administered orally has been shown to
signiﬁcantly restore photoreceptor function in affected
individuals [3]. LCA is an early-onset recessive human retinal
degeneration that can be caused by mutations in the gene
encoding retinal pigment epithelium 65 (RPE65), a key
protein involved in the production and recycling of 11-cis-
retinal (11-cis-RAL) in the eye. Approximately 15% of
patients with LCA have been found to have mutations in
Rpe65 [4,5]. Humans with this form of LCA and Rpe65
 /  mice
both have severely impaired rod and cone function [6]. The
biochemical block caused by the absence of Rpe65
 /  can be
bypassed with synthetic cis-retinoids administered orally,
resulting in a dramatic improvement in photoreceptor
physiology [7].
Somatic gene therapy has also been very successful in many
animal models of retinal degeneration [8]. Most notably, a
canine model with a naturally occurring Rpe65 deﬁciency,
the Rpe65
 /  dog, bears a phenotype similar to that of human
LCA patients and Rpe65
 /  mice. A recombinant adeno-
associated virus (rAAV) carrying wild-type (WT) Rpe65
(rAAV-Rpe65) restored visual function in this model of
childhood blindness [9].
The lecithin:retinol acyl transferase (LRAT)-deﬁcient
mouse is an animal model of LCA [10]. Mutations in the
gene encoding LRAT are associated with early-onset severe
retinal dystrophy, or LCA [11]. The prevalence of mutations
at this locus among patients with LCA is unknown but it is
likely uncommon, as three of 267 probands with severe early-
onset retinal dystrophy carried mutations in Lrat [11]. LRAT
is a key enzyme involved in storage of ROL in the form of
retinyl esters (REs) in speciﬁc structures known as retino-
somes [12]. Without LRAT, no 11-cis-RAL chromophore is
produced, and visual function is severely impaired [10].
Here, we aimed to investigate whether we could rescue
visual function by pharmacological intervention and gene
transfer therapy in LRAT-deﬁcient mice, and to assess the
advantages and disadvantages of oral administration of
retinoids and gene therapy. Comparison of these two
approaches is an important prelude for treatment in humans.
Methods
Animals
All animal experiments employed procedures approved by
the University of Washington and conformed to recommen-
dations of the American Veterinary Medical Association
Panel on Euthanasia and recommendations of the Associa-
tion of Research for Vision and Ophthalmology. Animals
were maintained in complete darkness, and all manipulations
were done under dim red light employing a Kodak No. 1
safelight ﬁlter (transmittance . 560 nm). Lrat
 /  mice were
generated and genotyped as described previously [10].
Typically, 6- to 12-wk-old mice were used in all experiments.
In the case of rAAV-Lrat treatment, 2- to 3-wk-old mice were
used.
rAAV1-VMD2-mLrat Vector
The pTR-UF5 backbone [13] was used for generation of a
pTR-VMD2-mLRAT plasmid construct. An EcoR1 fragment
containing the full-length mouse Lrat cDNA was excised from
pCR-TOPO II Blunt-Lrat and blunt ligated into the Not1 site
of the UF5 cassette, replacing the Gfp gene. Orientation of the
cDNA was conﬁrmed by restriction analysis and by sequenc-
ing. The Kpn1-Xba1 fragment of the placF-VMD2 plasmid
(from D. Zack, Johns Hopkins University) [14] includes the
 585/þ38 upstream region of the human VMD2 gene
(Chromosome 11q13) and was subcloned into the Kpn1-
Xba1 sites of the pTR-UF5 cassette (replacing the CMV
promoter) upstream of mouse Lrat cDNA. Sequence analysis
conﬁrmed the orientation and reading frame of the Lrat
cDNA. A serotype 1 AAV vector was produced in the
presence of a mini-Ad helper plasmid pDG38 by double
transfection of HEK293 cells, followed ﬁrst by puriﬁcation
over an iodixanol gradient and then by high-Q FPLC column
chromatography (Pharmacia, Uppsala, Sweden). Vector par-
ticle titers were determined by quantitative PCR. The rAAV1-
VMD2-mLrat vector was prepared at 4 3 10
13 physical
particles/ml. Exclusive RPE expression is seen in mice using
a Gfp reporter gene in an analogous rAAV1-VMD2 vector
(Glushakova and Hauswirth, unpublished data).
Preparation of Retinoids and Oral Gavage
All-trans-retinyl acetate (R-Ac), all-trans-R-Palm, all-trans-
RAL, all-trans-ROL, and 9-cis-RAL were purchased from
Sigma-Aldrich (St. Louis, Missouri, United States). 9-cis-ROL,
9-cis-R-Palm, 9-cis-R-Ac, and 9-cis-retinyl succinate (9-cis-R-Su)
were prepared from 9-cis-RAL. To prepare 9-cis-R-Ac, 100 mg
of 9-cis-RAL was reduced with 50 mg of sodium borohydride
in 0.7 ml of ethanol at 0 8C for 30 min, and 9-cis-ROL was
puriﬁed by organic extraction and dried under argon. Solid
9-cis-ROL and 80 mg of 4-dimethylaminopyridine were
dissolved in 0.4 ml of dry CH2Cl2, and 0.1 ml of acetic acid
anhydride was added. After 6 h at 10 8C, the reaction was
quenched with 0.1 ml of ethanol, CH2Cl2 was removed by
ﬂowing argon at 20 8C, and 9-cis-R-Ac was puriﬁed by organic
extraction and dried under argon. To prepare all-trans-R-Su
or 9-cis-R-Su, solid all-trans-ROL or 9-cis-ROL was dissolved in
0.2 ml of pyridine, with 100 mg of succinic acid anhydride
added and reacted overnight at 10 8C. CH2Cl2 was removed by
ﬂowing argon at 20 8C, and all-trans-R-Su or 9-cis-R-Su was
then puriﬁed by organic extraction and dried down under
argon. Retinoids were dissolved in pure canola oil (Western
Family Foods, Tigard, Oregon, United States), and concen-
trations were measured spectrophotometrically. Retinoids at
a ﬁnal concentration of 40 mg/ml in canola oil were
administered to Lrat
 /  mice using a 1-ml syringe and a 20-
gauge, 3.5-cm long gavage needle. Mice were allowed to rest
for 3 d following gavage. A single 5-mg dose (125 ll) of
retinoid was used to compare the different retinoids. Doses of
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Recovery of Vision in Blind Micegavaged 9-cis-R-Ac were 1, 2, 5, 10, 20, and 40 lmol to
determine dose effect. Multiple gavages of 9-cis-R-Ac were
performed with doses of 1, 5, and 10 lmol for up to ten
consecutive treatments.
Photobleaching of 9-cis-R-Ac Gavaged Mice
Lrat
 /  mice were gavaged four times with 10 lmol doses of
9-cis-R-Ac. Caged mice were placed on a bench under
ﬂuorescent light of average luminosity 600 cd 3 m
 2 and
allowed to photobleach for 1, 3, and 10 d. Mice were then
placed in the dark for 1 d, sacriﬁced, and the eyes collected
for retinoid analysis. A subset of mice were gavaged with 10
lmol 9-cis-R-Ac following photobleach, placed in the dark for
1 d, sacriﬁced, and the eyes collected for retinoid analysis.
Pupillary Light Responses
Pupillary light responses (PLRs) were recorded from dark-
adapted mice under infrared conditions using a CCD video
camera ﬁtted with close-up lens and an IR ﬁlter. Data analysis
was performed by video pupillometry. Light stimuli were
provided by a halogen source; wavelength and intensity were
manipulated with neutral density and narrow bandwidth (10
nm) interference ﬁlters (Oriel, Stratford, Connecticut, United
States). Irradiance measurements (W/m
2) were made using a
radiometer (Advanced Photonics International, White Plains,
New York, United States).
Analyses of Retinoids and Visual Pigments
All procedures were performed under dim red light as
described previously [7,15,16]. Retinoid analysis was per-
formed on an Agilent 1100 series HPLC equipped with a
diode array detector and Agilent Chemstation A.10.01
software (Agilent, Palo Alto, California, United States). A
normal phase column (Beckman Ultrasphere Si 5l, 4.6 3 250
mm [Beckman Instruments, Fullerton, California, United
States]) and an isocratic solvent system of 0.5% ethyl acetate
in hexane (v/v) for 15 min followed by 4% ethyl acetate in
hexane for 65 min at a ﬂow rate of 1.4 ml/min at 20 8C (total
80 min) with detection at 325 nm were used.
All of the experimental procedures related to the analysis
of dissected mouse eyes, derivatization, and separation of
retinoids have been described previously [7]. Rhodopsin and
isorhodopsin measurements were performed as described
previously [17]. Typically, two mouse eyes were used per assay,
and the assays were repeated three to six times. Whole livers
were homogenized for 30 s in 4 ml of retinoid derivatization
buffer (50 mM MOPS, 10 mM NH2OH, and 50% ethanol in
H2O [pH 7.0]) using a Polytron PT1200 motorized homoge-
nizer (Polytron, Bad Wildbad, Germany), and allowed to sit at
room temperature for 30 min. Retinoid analysis was
performed on 1 ml of liver homogenate following the same
extraction procedure used for eyes. Mouse blood was
collected from the eye socket using heparinized micro-
hematocrit capillary tubes (Fisher Scientiﬁc) immediately
following removal of the eyes. Blood was transferred to a
tared 1.5-ml Eppendorf tube and weighed (Eppendorf,
Hamburg, Germany). Next, 1 ml of retinoid derivatization
buffer was added and vortexed (Eppendorf Mixer 5432) for 30
min high speed at room temperature. Blood was then used for
retinoid analysis following the same extraction procedure
used for eyes. Rhodopsin from Lrat
 /  mice treated with
rAAV-Lrat virus was isolated by immunoafﬁnity chromatog-
raphy as described previously [18].
Electroretinography
Mice were anesthetized by intraperitoneal injection using
20 ll/g body weight of 6 mg/ml ketamine and 0.44 mg/ml
xylazine diluted with 10 mM sodium phosphate (pH 7.2),
containing 100 mM NaCl. The pupils were dilated with 1%
tropicamide. A contact lens electrode was placed on the eye,
and ground electrodes were placed on the scalp and tail.
Electroretinograms (ERGs) were recorded with the universal
testing and electrophysiologic system UTAS E-3000 (LKC
Technologies, Gaithersburg, Maryland, United States). The
light intensity was calibrated and computer-controlled. The
mice were placed in a Ganzfeld chamber, and scotopic
responses to ﬂash stimuli were obtained from both eyes
simultaneously. Flash stimuli had a range of intensities ( 3.7
to 2.8 log cd s m
 2), and white light ﬂash duration was
adjusted according to intensity (from 20 ls to 1 ms). Three to
ﬁve recordings were made with intervals of 10 s or longer, and
for higher intensity trials, intervals were 10 min or as
indicated. Five animals were typically used for recording of
each point in gavage conditions. ERGs were performed on all
mice treated with rAAV-Lrat. The results were examined
using the one-way ANOVA test.
Recordings from Rods
Suction electrode recordings from rod photoreceptors
followed published procedures [19]. In brief, a small piece of
retina was shredded with ﬁne needles, and the resulting
suspension was placed in a chamber on the microscope stage.
Single outer segments were drawn by suction into a tightly
ﬁtting glass electrode, and changes in outer segment current
in response to brief light ﬂashes were measured. All
procedures were carried out using infrared illumination
(.950 nm). Mice for these experiments were dark adapted for
at least 12 h. C57Bl/6J mice were used as controls. All
experiments were carried out at 35–37 8C.
Liver RA Analysis
The method of Kane et al. was used with slight variation
[20]. Whole mouse livers were removed from Lrat
 /  mice
after eye removal during the above experiments. Livers were
weighed and then frozen in liquid N2. Frozen livers were
transferred to a 15-ml glass centrifuge tube (Corex #8441
[Corning Life Sciences, Acton, Massachusetts, United States])
containing ice-cold phosphate buffered saline (PBS) at a 1:4
ratio of liver to PBS (w/v) to make a 25% homogenate and
were homogenized 30 s using a Polytron PT1200 motorized
homogenizer. Next, 500 ll of homogenate was transferred to
an 8-ml glass tube on ice, and 1 ml of ice-cold ethanol and 5 ll
of 5 M NaOH were added and vortexed. Finally, 4 ml of ice-
cold hexane was added, and the mixture was vortexed and
centrifuged for 5 min using a Beckman J2-HS centrifuge with
a JS13.1 swinging bucket rotor for 5 min at 4,000 rpm, 4 8C.
The hexane layer was removed and discarded. The hexane
extraction was repeated one more time. To extract RA, 20 ll
of 12 M HCl was added to the remaining aqueous solution
and vortexed. Hexane extraction was performed as above, but
hexane was retained from both extractions and dried down
under blowing argon at 20 8C. Residue was dissolved in 300 ll
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Recovery of Vision in Blind Miceof 1,000:4.3:0.675 hexane:2-propanol:acetic acid (v/v) and
transferred to an amber glass HPLC vial with glass insert.
For the ﬁrst separation, 100 ll of sample was injected into
the Agilent 1100 HPLC described above. Two tandem normal
phase columns were used. The ﬁrst column was a Varian
Microsorb Silica 3l, 4.63100 mm column (Varian, Palo Alto,
California, United States), and the second was the Beckman
column described above. An isocratic solvent system of
1,000:4.3:0.675 hexane:2-propanol:glacial acetic acid (v/v) at
a ﬂow rate of 1 ml/min at 20 8C with detection at 355 nm was
used [21]. The system was calibrated using standards of all-
trans-RA and 9-cis-RA purchased from Sigma-Aldrich.
Immunocytochemistry and Histology
Procedures have been described previously [22]. Anti-
LRAT monoclonal antibody [10] was directly coupled with
Alexa488, or detected by anti-mouse IgG labeled with Cy3.
Sections were analyzed under an epiﬂuorescence microscope
(Nikon, Tokyo, Japan). Low magniﬁcation images were
captured with a digital camera (ORCA-ER, Hamamatsu
Photonics, Bridgewater, New Jersey, United States) or a Zeiss
LSM 510 NLO confocal microscope (Zeiss, Oberkochen,
Germany).
Retinas of 17-mo-old Lrat
 /  and WT mice were marked,
enucleated, and immersed immediately in a ﬁxative of 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4).
Following ﬁxation for 4–5 h at 4 8C, the eyecup containing
the optic nerve was postﬁxed in 1% osmium tetroxide in
phosphate buffer, dehydrated through a series of graded
ethanol, and embedded in Spurr’s resin. Sections 0.5–1 lm
thick were imaged using a Leica (Wetzlar, Germany) DM-R
microscope with Prior stage, using Syncroscan RT software
from Syncroscopy (Frederick, Maryland, United States). The
scaling for measurement is 182 nm/pixel and 5.5 pixels/
micrometer at 403. The thicknesses of rod outer segments
(ROSs) in micrometers as a function of distance from the
ONH were measured after import into Deneba Canvas
software (ACD Systems, Saanichton, British Columbia, Can-
ada).
Transmission EM
For transmission electron microscopy (EM), mouse eyecups
were ﬁxed primarily by immersion in 2.5% glutaraldehyde
and 1.6% paraformaldehyde in 0.08 M PIPES (pH 7.4)
containing 2% sucrose, initially at room temperature for
;1 h, then at 4 8C for the remainder of 24 h. The eyecups
were then washed with 0.13 M sodium phosphate (pH 7.3),
and secondarily ﬁxed with 1% OsO4 in 0.1 M sodium
phosphate (pH 7.4), for 1 h at room temperature. The
eyecups were dehydrated through a CH3OH series and
transitioned to the epoxy embedding medium with propylene
oxide. The eyecups were embedded for sectioning in Eponate
812. Ultrathin sections (60–70 nm) were stained with aqueous
saturated uranium acetate and Reynold’s formula lead citrate
prior to survey and micrography with a Philips CM10 EM
(Philips Electron Optics, Eindhoven, The Netherlands).
Statistical Analyses
Data were expressed as mean 6 standard error of the mean
(SEM) Liver data was presented as mean 6 SEM of one-
quarter of whole livers. Blood data was presented as mean 6
SEM per 100 mg of blood.
Results
Lrat
 /  Mice Are a Model of Vitamin A Deficiency
We analyzed the retinoid content of Lrat
 / and Lrat
þ/þmice
to determine how the absence of LRAT inﬂuenced the levels
of the 11-cis-RAL chromophore and its derivatives. Lrat
 / 
mice had diminished levels of all-trans-retinoids in the eye
[10] and 100- to 1,000-fold lower levels of cis-retinoids
compared with WT mice (Figure S1). Cis-retinoids were also
Table 1. Retinoid Analysis of Tissues from Lrat
 /  Mice Gavaged with 20 lmol 9-cis-R-Ac as a Function of Post-Treatment Time
Organ Compound Recovery Time
Lrat
 /  Lrat
þ/þ No
Treatment
0 h 2 h 5 h 10 h 24 h 48 h 72 h 96 h
pmol SD pmol SD pmol SD pmol SD pmol SD pmol SD pmol SD pmol SD pmol SD
Blood REs 1.0 1.7 235.3 205.4 33.7 58.5 6.6 1.6 10.9 6.7 1.2 2.2 0.7 1.2 0.4 0.8 8.3 6.3
9-cis-R-Ac 0.0 0.0 24.0 27.4 4.1 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0
9-cis-Retinal oximes 0.0 0.0 366 275.7 87.6 51.5 28.8 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0
9-cis-Retinol 0.0 0.0 86.8 60.1 11.1 19.1 2.9 0.4 0.0 0.0 6.1 10.5 2.1 3.6 0.0 0.0 0 0
All-trans-retinol 6.2 3.0 35.6 25.2 6.0 10.2 2.2 0.4 6.4 11.0 3.5 6.1 10.1 3.6 2.6 4.4 13.3 8.5
Liver REs 18.2 6.5 3,509.9 1,773.3 5,169.0 1,729.9 1,509.6 165.8 348.8 119.1 79.8 28.7 64.2 22.9 64.2 12.9 4.3 3 10
5 4.7 3 10
4
9-cis-R-Ac 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0
9-cis-Retinal oximes 0.0 0.0 5,390.7 3,678.3 9,656.4 6,105.6 894.3 25.8 53.4 92.4 6.3 10.8 0.0 0.0 26.1 4.2 0 0
9-cis-Retinol 0.0 0.0 1,601.4 1,491.6 2,148.6 1,875.4 277.8 35.6 39.0 67.5 39.0 28.7 15.7 9.5 13.6 2.4 0 0
All-trans-retinol 147.8 18.8 1,341.0 1,182.1 2,052.2 1,753.3 884.2 61.1 401.0 694.7 253.4 2.4 218.9 106.3 310.9 65 635.8 138.1
Eye REs 1.1 0.5 8.8 0.5 19.2 14.4 3.2 5.5 20.2 10.8 4.6 4.2 0.9 0.9 3.2 0.2 97.8 30.2
9-cis-R-Ac 0.0 0.0 0.6 1.0 4.9 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0
9-cis-Retinal oximes 0.0 0.0 108.0 39.9 300.0 35.2 351.0 15.7 328.6 57.7 299.2 51.0 334.8 35.5 371.5 5.2 3.7 0.36
9-cis-Retinol 0.0 0.0 50.6 10.2 76.1 34.9 36.6 3.9 17.3 14.3 6.2 5.2 3.1 3.4 0.0 0.0 0 0
All-trans-retinol 8.9 1.5 25.3 6.6 46.1 13.4 35.2 2.5 25.5 10.1 17.4 2.2 12.5 1.4 15.7 4.4 13.5 0.7
Retinoids were analyzed by HPLC as described in Methods. The amounts are expressed per liver, eye, and 100 mg of blood.
DOI: 10.1371/journal.pmed.0020333.t001
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Recovery of Vision in Blind Miceobserved in Rpe65-deﬁcient mice, but at 5% of the level of
WT mice [23]. Formation of cis-retinoids is likely due to the
propensity of retinoids to spontaneously isomerize and
become trapped by opsin in the photoreceptors. Lrat is
expressed in the liver as well as in the eye; the amount of REs
in the liver of Lrat
 /  mice was more than 20,000-fold lower
than WT mice (Table 1). Circulating all-trans-ROL from the
diet was also reduced, producing lower retinoid concen-
trations in the blood (Table 1). No visual pigments were
measurable in the Lrat
 /  mice by direct spectrophotometric
analysis.
Visual Pigment in Lrat-Deficient Mice Is Restored by Oral
Gavage with 9-cis-Retinoid
We synthesized a series of 9-cis-retinoids and ester
derivatives to determine whether the phenotype of Lrat
 / 
mice could be reversed by chemically bypassing the LRAT-
catalyzed metabolic step (Figure 1A). Oral gavage of these
exogenous retinoids led to the generation of visual pigment
in Lrat
 /  mice. Visual pigments were measured chromato-
graphically by the retention of 9-cis-RAL oximes (Figure 1B)
or spectrophotometrically (unpublished data) by the level of
isorhodopsin (i.e., opsin þ 9-cis-RAL chromophore). Both
methods were highly reproducible and yielded similar results.
Visual pigment was rescued in Lrat
 /  mice by oral gavage
with 9-cis-RE, 9-cis-RAL, or 9-cis-ROL, whereas all-trans
isomers were ineffective. Among REs, 9-cis-R-Ac and 9-cis-R-
Su were most efﬁcient (by weight per dose) in restoring
pigment (Figure 1B). Esters are readily metabolized in the
small intestine and are more inert than RALs and ROLs
(Figure 1C). For these reasons 9-cis-R-Ac was chosen for the
remaining experiments.
Kinetics of Visual Pigment Rescue and Retinoid Clearance
by Oral 9-cis-R-Ac in Lrat-Deficient Mice
Gavage with 9-cis-R-Ac produced a transient increase in
retinoid levels in the liver and a more sustained increase in
levels in the eye (Figure 2). The visual pigment was restored in
Lrat
 /  mice 4–5 h after gavage with 9-cis-R-Ac. Visual
pigment levels measured by HPLC remained nearly constant
for 96 h (Figure 2G). By 120 d following a single oral gavage
with 9-cis-R-Ac, dark-reared Lrat
 /  mice retained more than
50% of the pigment (Figure 2H). Considering that ;10% of
ROSs are phagocytosed daily and replaced by newly formed
discs at their base [24], these data suggest that even in the
absence of LRAT, the chromophore may be efﬁciently
recycled via hydrolysis of isorhodopsin and directional
transport of 9-cis-RAL from the RPE to the photoreceptors.
Despite the absence of LRAT, REs were formed transiently
in the liver and blood after gavage, suggesting that another
enzyme is capable of the esteriﬁcation reaction, such as acyl
coenzyme A:diacylglycerol acyltransferase [25]. In less than 10
h, more than 90% of retinoids, including nuclear receptor
activators all-trans-RA and 9-cis-RA, were cleared (Figure 2I
and 2J; Table 1). Thus within 4–5 h after gavage, peripheral
hydrolysis of REs is faster than synthesis, and retinoids are
quickly metabolized or secreted. These data suggest efﬁcient
uptake of 9-cis-retinoids by the visual pigment and rapid
clearance of excess exogenous retinoids from key metaboliz-
ing and transporting tissues, lowering the potential for
toxicity.
Figure 1. Retinoid Structures, Specificity of Retinoids in Regeneration of Visual Pigment, and Model of Absorption of 9-cis-R-Ac in Mammals
(A) Structures of retinoids used for gavage studies.
(B) Levels of all-trans-RAL oximes, 9-cis-RAL oximes (corresponding to formation of visual pigment isorhodopsin), and all-trans-REs in Lrat
 / mouse eyes
gavaged with 5 mg of each retinoid before 48–72 h dark adaptation (n   3, data shown with standard deviation [SD]).
(C) Model of absorption of 9-cis-R-Ac in mammals.
DOI: 10.1371/journal.pmed.0020333.g001
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Recovery of Vision in Blind MiceRegeneration of Visual Pigments Improves the
Morphology of Rod Photoreceptors
Maximal visual pigment formation required ;4 lmol of 9-
cis-R-Ac (Figure 3A). The level of isorhodopsin in the eye of
Lrat
 /  mice after a single gavage was ;60%–70% of the WT
level of rhodopsin (Figure 3). When total opsin was isolated by
immunoafﬁnity chromatography, the UV-vis spectrum
showed that all opsin present in the retina was regenerated
(unpublished data), suggesting that all opsin was properly
folded but is present in ROS at lower amounts than in WT
ROS. Multiple 5- to 10-lmol doses spread over weeks
produced almost full recovery of WT levels of visual pigment
(Figure 3B).
Exposure to light released the isomerized chromophore as
all-trans-ROL in treated Lrat-deﬁcient mice (Figure 3C, black)
with kinetics proportional to the intensity of the bleaching
light. Subsequent gavages restored the chromophore efﬁ-
ciently (Figure 3C, red). Multiple gavages were effective in
mice up to 12 mo old (Figure S2A). Histological analysis
showed that the retina of untreated Lrat
 /  mice degenerated
slowly (Figure S2B), leaving functionally intact photorecep-
tors available for treatment in the older mice.
Since ROS structural morphology is thought to be depend-
ent on functional rhodopsin, this result (in conjunction with
recycling of the chromophore as discussed above) suggested
that ROS morphology might be improved with treatment. We
used EM to evaluate the RPE-ROS interface. Control and
gavaged Lrat-deﬁcient mice were analyzed. The thickness of
the ROS layer was substantially improved, from 10.7 6 0.16
lm to 14.2 6 2.2 lm in treated mice, and the RPE-ROS
interface showed closer apposition in comparable areas of
the retina (Figure 3D and 3E; n ¼ 5, p , 0.002).
Improvement of Rod Responses in Lrat
 /  Mice Treated
with 9-cis-R-Ac
Outer segment membrane currents of Lrat
þ/þ and Lrat
 / 
rods were directly measured with suction electrodes (Figure
4). Rods of untreated Lrat
 /  mice were ;2,000-fold less
sensitive than Lrat
þ/þrods. Gavage of Lrat
 / mice with 9-cis-R-
Ac restored near-WT sensitivity, although several treatments
were required.
Figure 4A and 4B show ﬂash families recorded from Lrat
þ/þ
and Lrat
 /  rods. Lrat
 /  rods had a smaller dark current than
Lrat
þ/þrods (mean 6 SEM: Lrat
 / , 4.8 6 0.4 pA, n¼21; Lrat
þ/þ,
15 6 1 pA, n ¼ 22). In addition, the dim ﬂash response
reached a peak more quickly in Lrat
 /  rods (Lrat
 / , 108 6 4
msec; Lrat
þ/þ, 228 6 9 msec). Sensitivity was estimated by
Figure 2. Retinoids in the Liver and Eyes of Lrat
 /  Mice after 9-cis-R-Ac Treatment
(A–F) Normal-phase HPLC analysis of nonpolar retinoids extracted from the tissues of dark-adapted Lrat
þ/þ or Lrat
 /  mice following gavage with
retinoids. Peaks marked * represent the solvent change artifact, and peaks labeled (1) indicate an unidentified non-specific compound with kmax¼270
nm. In all experiments, mice were dark-adapted for 48 h after gavage. Shown are results from eyes of dark-adapted control Lrat
þ/þ (gray) and Lrat
 / 
mice (black) (A); eyes of dark-adapted Lrat
 /  mouse gavaged with all-trans-R-Ac (B); eyes of dark-adapted Lrat
 /  mouse gavaged with 9-cis-R-Ac (C);
liver tissue from dark-adapted control Lrat
þ/þ (gray) and Lrat
 /  (black) mice (D); liver tissue from dark-adapted Lrat
 /  mouse gavaged with all-trans-R-
Ac (E); and liver tissue from dark-adapted Lrat
 /  mouse gavaged with 9-cis-R-Ac (F).
(G–J) Time course of the levels of nonpolar and polar retinoids in the tissues of Lrat
 /  mice following gavage with 9-cis-R-Ac measured by HPLC. After
gavage, mice were dark adapted for indicated time before HPLC analysis (n   3, data shown with SD). The graphs depict: a short time course of 9-cis-
RAL oxime levels detected in Lrat
 /  mice eyes following a 20 lmol gavage of 9-cis-R-Ac (G); a longer time course of 9-cis-RAL oxime levels in Lrat
 / 
mice eyes following a 20 lmol gavage of 9-cis-R-Ac (H); time course of 9-cis-ROL blood levels in Lrat
 /  mice following gavage with 20 lmol 9-cis-R-Ac
(I); and time course of RE and RA levels in liver of Lrat
 /  mice following a 20 lmol gavage with 9-cis-R-Ac (J).
DOI: 10.1371/journal.pmed.0020333.g002
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Recovery of Vision in Blind Miceplotting the amplitude of the response versus ﬂash strength
(Figure 4E). The ﬂash necessary to produce a half-maximal
response was ;2,000 times brighter in Lrat
 /  rods (Lrat
 / ,
33,000 6 2,000 photons/lm
2; Lrat
þ/þ,1 86 1 photons/lm
2).
The decreased dark current, decreased sensitivity, and faster
response kinetics of Lrat
 /  rods were all consistent with
bleaching adaptation produced by residual opsin activity in
the absence of a chromophore [26–28]. This phenotype is
more severe than that of Rpe65
 /  rods, which are ;150-fold
less sensitive than normal [16]. This may be explained by the
lower levels of 9-cis-RAL (see Figure S1) [23] seen in Lrat
 / 
mice compared with Rpe65
 /  mice. The sensitivity of Lrat
 / 
rods was markedly enhanced when the mice were gavaged
with 9-cis-R-Ac. Figure 4C and 4D show ﬂash families
recorded from Lrat
 /  mice rods after a single gavage (Figure
4C) and multiple gavages (Figure 4D). Figure 4E shows the
corresponding stimulus-response relations. The dark current
was restored to near-normal levels after a single treatment
with 9-cis-R-Ac (15 6 1 pA, n¼10), and the half-maximal ﬂash
strength was reduced to 390 6 20 photons/lm
2 (n ¼ 10).
Correcting for the ;3-fold reduced quantum efﬁciency from
rhodopsin to isorhodopsin, the sensitivity of singly-treated
rods was ;8-fold less than normal. Treatment with multiple
doses of 9-cis-R-Ac increased the sensitivity. The half-maximal
ﬂash strength after three treatments was 87 6 6 photons/lm
2
(n ¼ 26). Correcting for the lowered 9-cis-RAL quantum
efﬁciency, this is within a factor of two of WT mouse rod
responses.
Restoration of ERG in Lrat
 /  Mice Treated with 9-cis-R-Ac
ERG responses in treated and control Lrat
 /  mice
conﬁrmed the improvements described above for individual
rod signaling. The a-wave (generated by photoreceptors) and
b-wave (generated by bipolar cells) of dark-adapted Lrat
 / 
mice were about 5% of the amplitude of those observed in
WT mice (Figure 4F). The Lrat
 /  b-wave was also reduced
substantially, in proportion to the decreased a-wave. Follow-
ing multiple 9-cis-R-Ac gavage treatment, ERG a- and b-wave
amplitudes increased to about half of WT levels (Figure 4F
and 4G).
AAV-Lrat Rescue of Visual Function in Lrat-Deficient Mice
As an alternative to oral gavage, we tested the ability of
treatment with rAAV carrying the Lrat gene to restore
function in Lrat-deﬁcient mice. Immunolocalization of LRAT
in rAAV-Lrat-treated Lrat
 / mouse eyes showed expression in
the vicinity of the injection site (Figure 5A) and was not
uniform (Figure 5B). Higher resolution ﬂat-mounted immu-
nocytochemistry showed that Lrat was expressed speciﬁcally
in the RPE of treated mice, but was not observed in control
mice (Figure 5C and 5D). Treatment led to production of
rhodopsin as determined by retinoid analysis and isolation of
rhodopsin (Figure S3). The measurements of the level of
rhodopsin as measured both directly by spectroscopy and
indirectly by cis-retinoids (11- or 9-) are in good agreement
(see also [29]).
Treatment with rAAV-Lrat increased the sensitivity of the
a- and b-waves in Lrat
 /  mice (Figure 5E and 5F). The rescue
was comparable to 9-cis-R-Ac-treated mice. The largest
improvement in sensitivity was seen 6 wk after injection of
the virus, while the response gradually declined from 6–31 wk
post-treatment (Figure 5F). The improvement in a- and b-
Figure 3. Levels of 9-cis-RAL Oximes in the Eyes of Lrat
 /  Mice after a Single or Multiple Dose of 9-cis-R-Ac
(A) The level of 9-cis-RAL in Lrat
 /  mouse eyes after a varying dose of 9-cis-R-Ac.
(B) The level of 9-cis-RAL in Lrat
 /  mouse eyes after a varying size and number of doses of 9-cis-R-Ac. The solid gray line represents a maximal level of
isorhodopsin as measured by the level of 9-cis-retinal oximes in Lrat
 /  mouse eyes after ten gavages; dashed gray line indicates the SD. The maximal
level of isorhodopsin is comparable to the level of rhodopsin in WT mice (blue dotted line, shown as pmol of 11-cis-retinal/eye).
(C) The level of 9-cis-RAL in Lrat
 / mouse eyes after 9-cis-R-Ac treatment and light exposure or after exposure to light and re-gavage (n   3, data shown
with SD).
(D and E) Changes in the RPE-ROS interface in control Lrat
 /  mice and Lrat
 /  mice treated with 9-cis-R-Ac. Treated Lrat
 /  mice were gavaged with 9-
cis-R-Ac (10 lmol per gavage) six times, 3 d apart, and analyzed (D). Control retina from age-matched (8 wk old) untreated Lrat
 / mice (E). Considerably
improved RPE-ROS processes were observed in all treated mice. RPE, retinal pigment epithelium; ROS, rod outer segments; IS, inner segments. Scale bar,
10 lm.
DOI: 10.1371/journal.pmed.0020333.g003
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Recovery of Vision in Blind Micewave sensitivity following rAAV-Lrat treatment showed
considerable variability, most likely due to the inherent
variability in the amount of vector surgically delivered to
these small eyes (Figure S4).
The visual pigment of rAAV-Lrat-treated Lrat-deﬁcient
mice was augmented by oral gavage with 9-cis-R-Ac as
described above. This augmentation was observed by HPLC
separation and quantiﬁcation of 11-cis-RAL oximes (a result
of rAAV rescue) and 9-cis-RAL oximes (Figure S3A–S3C).
ERG responses in Lrat
 /  mice treated with rAAV-Lrat and 9-
cis-R-Ac further improved to reach the levels of 9-cis-R-Ac
treated mice (Figure S3D and S3E).
Both rAAV-Lrat and 9-cis-R-Ac Treatment Restore PLRs in
Lrat-Deficient Mice
PLRs were used to assay rescue of retinal signaling to the
brain (Figure 6). Restoration of PLR implies successful
transmission of photic information to the olivary pretectum
of the brain. PLR of control Lrat
 /  mice were ;3.5 log units
less sensitive than heterozygous or WT animals (Figure 6I).
Irradiance-response relations for PLR showed that both 9-cis-
R-Ac and rAAV-Lrat treatments each increased Lrat
 /  PLR
sensitivity by ;2.5 log units (Figure 6I). Figure 6A–6D and
Video S1 compare the PLRs of the same Lrat
 /  mouse before
and after 9-cis-R-Ac treatment, illustrating the signiﬁcant
gain in photosensitivity observed following treatment. Sim-
ilarly, Figure 6E–6H and Video S2 show that rAAV-Lrat
treatment conferred substantially increased sensitivity to
light stimuli as compared with the control contralateral eye
of the same animal. Similar improved PLR were recently
obtained for Rpe65
 /  mice treated with 9-cis-RAL [30].
Complementarity of Viral and Pharmacological Rescue of
Lrat
 /  Mice
To determine if viral and pharmacologic treatments could
be combined, we performed oral gavage on Lrat
 /  mice
previously rescued with rAAV-Lrat. Biochemical augmenta-
tion of visual pigment was observed directly, as the elution of
11-cis-RAL oximes (a result of AAV rescue) and 9-cis-RAL
oximes (produced by oral gavage) were well separated on a
HPLC column (Figure S3A–S3C). While ERG amplitudes of
virally-rescued animals were below those seen in mice rescued
by oral gavage, ERG responses in Lrat
 /  mice treated with
rAAV-Lrat and 9-cis-R-Ac further improved to reach the
levels of 9-cis-R-Ac treated mice (Figure S3D and S3E).
Discussion
Here, we demonstrate that inborn errors of metabolism
leading to blinding diseases can be successfully treated by
gene therapy or pharmacological intervention. Visual pig-
ment formation, tissue morphology, and visual function as
measured by single-cell recordings, ERG, and PLR were
signiﬁcantly improved after treating a mouse model of LCA
due to deﬁciency in LRAT with intraocular injections of
rAAV-Lrat or by oral gavage with 9-cis-R-Ac. Pharmacological
Figure 4. Rescue of Visual Responses Measured by Single-Cell Recording and ERG Responses of single Lrat
þ/þ and Lrat
 /  Rods
(A–D) Flash families measured for a Lrat
þ/þrod (A), a control Lrat
 / rod (B), a Lrat
 / rod after a single gavage with 9-cis-R-Ac (C), and a Lrat
 / rod after
three gavages with 9-cis-R-Ac (D). Each panel superimposes average responses to five to 20 repeats of a flash, with the flash strength increasing by a
factor of two for each successively larger response.
(E) Stimulus-response relations for the same cells in (A–D). Maximal response amplitudes are plotted against the flash strength. Fits are saturating
exponential functions, used to estimate the strength of the flash producing a half-maximal response (Lrat
þ/þ, 26 photons/lm
2; Lrat
 / , 43,000 photons/
lm
2; singly treated Lrat
 / , 590 photons/lm
2; and multiply treated Lrat
 / , 69 photons/lm
2).
(F and G) Comparison of WT mice scotopic single flash ERG to Lrat
 /  9-cis-R-Ac gavaged mice and Lrat
 /  and Lrat
þ/þ control mice. Lrat
 /  mice were
gavaged nine times with 5 lmol 9-cis-R-Ac over a 1-mo time period (n   3, data shown with SD).
DOI: 10.1371/journal.pmed.0020333.g004
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Recovery of Vision in Blind Miceinterventions to treat some forms of retinal disease have been
attempted in animal models of human blinding conditions,
among them treatment of rd1 mice with the Ca
2þ channel
blocker D-cis-diltiazem and other blockers that prevent rise of
intracellular Ca
2þ to toxic levels [31], and treatment of rd1
mice with leukemia inhibitory factor, which is involved in the
down-regulation of genes involved in synthesis and degrada-
tion of cGMP [32]. Other studies have used inhibitors of
apaptosis, an approach applicable to a wide range of retinal
disorders. Several studies suggest that intraocular injection of
neurotrophic factors (e.g., brain-derived neurotrophic factor
and ciliary neurotropic factor ) can protect the murine retina
from light damage, or delay photoreceptor degeneration in
animal models (for example [33]). In most cases, the beneﬁcial
effects of treatment last less than a month and require
repeated administrations.
Dryja and colleagues showed that ROL supplementation
slows the rate of photoreceptor degeneration caused by a
T4M rhodopsin mutation in mice [34]. More recently, 9-cis-
RAL application to Rpe65
 / mice resulted in formation of an
active iso-rhodopsin and an improvement in the ERG of these
animals for a time period of up to 6 mo after treatment [7,16].
The Rpe65 mutation blocks the retinoid cycle by preventing
the generation of 11-cis-RAL, the chromophore of visual
pigments. Oral application of 9-cis-RAL circumvents this
blockage. The blockade has also been rescued by rAVV-Rpe65
gene transfer method in naturally Rpe65-deﬁcient dogs [9].
Rpe
 /  mice display enhanced esteriﬁcation properties that
could lead to trapping 9-cis-retinoids in the form of 9-cis-REs.
Thus it was very important to examine if this pharmaco-
logical approach would be successful in mice lacking the key
esterifying enzyme. Combining oral retinoid treatment (using
next-generation retinoid pro-drugs) and viral rAAV-Lrat
somatic gene therapy in Lrat
 /  mice led to remarkable
rescue of visual functions in these mice. We found that both
methods increased ERG responses from ;5% of wild-type
levels in Lrat
 /  mice to ;50% of wild-type levels in treated
Lrat
 /  mice. Retinoid treatment led to increased levels of
visual chromophore from undetectable levels to 600 pmoles
per eye. The ROS dark current was restored to near-normal
levels of 15 6 1 pA after a single treatment with 9-cis-R-Ac,
and the half-maximal ﬂash strength after three treatments
was 87 6 6 photons/lm
2. Correcting for the lowered 9-cis-
RAL quantum efﬁciency, this is within a factor of 2 of WT
mouse rod responses. Irradiance-response relations for PLR
showed that both 9-cis-R-Ac and rAAV-Lrat treatments each
increased Lrat
 /  PLR sensitivity by ;2.5 log units.
Rescue of Visual Functions by Pharmacological Treatment
and Gene Transfer
Our previous ﬁndings described the Lrat
 /  mouse as a
model of LCA with pathological characteristics similar to
those found in patients affected by mutations in the LRAT
gene [11]. In the current study, we demonstrate that visual
functions can be rescued in Lrat
 /  mice, as measured by
recovery of visual chromophore and pigment, and by single-
cell and ERG responses. Successful restoration of retinotectal
signaling, as measured by pupillary responses, was also
achieved. Pharmacological treatment was successful in every
experimental trial, with restoration of about half-maximal
ERG responses compared with the WT mice. While full
restitution of the ERG could not be obtained in Lrat
 /  mice
in the tested experimental conditions, our ﬁnding of nearly
complete restitution of single cell responses suggests that
remodeling of the neuronal retina in Lrat
 /  may limit
functional rescue [35]. Possibly, the ROS of Lrat
 /  mice are
shorter as a result of damage caused by phototransduction
triggered by free opsin [27,28], a phenomenon reminiscent of
ROS shrinkage under continuous stimulation by light (photo-
stasis) or as a result of vitamin A deprivation [36–38].
However, the rod photoreceptors resist complete degener-
ation in Lrat
 /  mice (even in 17-mo-old mice raised in a
normal light cycle), while the cones undergo almost complete
Figure 5. Immunocytochemistry and ERG of rAAV-Lrat-Treated Lrat
 / 
Mice
(A) Immunolocalization of LRAT (green) in rAAV-Lrat treated Lrat
 / 
mouse eye. Anti-LRAT antibody was directly labeled by Alexa 488.
Expression of LRAT is locally restricted (arrowheads) in the eye. Nuclei are
stained by Hoechst 33342 (blue).
(B) Higher-power magnification image of (A). LRAT (green) is observed
specifically in the RPE cell layer.
(C) Subcellular localization of LRAT in rAAV-Lrat treated Lrat
 /  mouse
eye. RPE cells were labeled by anti-LRAT and detected by Cy3-labeled
secondary antibody (red). Nuclei are stained by Hoechst 33342 (blue).
RPE cell layer was mounted flat on a coverslip and imaged. LRAT is
localized in the internal membrane of the RPE cells. Similar localization
was observed for WT mouse RPE cells [12].
(D) Control flat-mounted RPE cell layer of untreated Lrat
 /  mouse. Anti-
LRAT antibody does not show any non-specific labeling. Bars indicate
100 lm.
(E) Comparison of scotopic single flash ERG of rAAV-Lrat treated, Lrat
þ/þ,
and Lrat
 /  control mice as measured by a-wave amplitudes, (n   16,
data shown with SD).
(F) A plot of a-wave amplitudes at 2.8 cd s m
 2 intensity as a function of
post-treatment time for rAAV-Lrat treated mice.
DOI: 10.1371/journal.pmed.0020333.g005
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Recovery of Vision in Blind Micedegeneration. In fact, the ROS in 17-mo-old mice are nearly
as long as in 2-mo-old Lrat
 /  mice (see Figure S2B). A similar
observation has been made for Rpe65-deﬁcent mice [39].
Multiple gavages during a 2-wk period led to morphological
restoration once the ROS completed the 12-d cycle of
phagocytosis and renewal [24]. The improved rescue after
multiple gavages was conﬁrmed not only by retinoid analysis
by HPLC, but also by morphological analysis and electro-
physiological tests. In single-cell recordings, the ;3-fold
difference in sensitivity between WT ROS and ROS from
multiply treated Lrat
 /  mice could be accounted for by the
discrepancy in the quantum yield of opsin loaded with 11-cis-
RAL and 9-cis-RAL chromophores. These differences are
small compared to the range of intensities over which vision
operates [40].
Oral synthetic retinoid treatment was remarkably success-
ful in rescuing the Lrat
 /  phenotype because of the highly
speciﬁc mechanism of ROL transport and retention [41].
ROL absorption is followed by entrapment of REs in the lipid
droplets of hepatic stellate cells and the retinosome struc-
tures found in the RPE [12,42]. ROL is mobilized from the
intestine or liver as ROL ester components of chylomicrons
or as ROL complexed with ROL-binding protein and trans-
thyretin or albumin [12,42–44]. Cis-retinoids employed in this
study used the existing retinoid transport system and were
efﬁciently delivered to the eye (see Figure 2C).
We have chosen 9-cis-retinoids in our studies because they
display higher stability than 11-cis-retinoids in storage and
handling and at the low pH of the stomach, and they require
simpler chemical synthesis, yet they share many advantages of
11-cis-retinoids, including the efﬁcient formation of highly
sensitive pigments and a similar metabolic pathway of
degradation and transport in mammals. Based on their
chemical properties, pro-drug cis-REs appear to be a better
alternative to RAL or ROL because of their stability and
efﬁcient metabolic transformation to active 9-cis-RAL in the
eye. Interestingly, other pro-drugs, such as vitamin E, are also
delivered as more hydrophilic succinate esters [45]. Such REs
lower the hydrophobicity and non-speciﬁc diffusion of these
lipid-soluble compounds within the membranes of the
digestive tract. In the RPE, 9-cis-ROL is transiently trapped
as REs (Table 1), which then undergo hydrolysis and oxidation
to regenerate the active chromophore 9-cis-RAL (see Figure
1C). The absorption and transformation of cis-retinoids might
be similar to that of all-trans-retinoids because of the multiple
overlapping activities of the enzymes involved and their low
speciﬁcity toward different retinoid isomers [41].
Viral treatment was also effective in restoring the normal
retinoid cycle in the eye and rescuing visual function. The
rescue peaked at 6 wk and then slowly decayed. The
expression of Lrat was localized to the injection site, but
signiﬁcant rescue of visual pigment rhodopsin was observed
(;50%). More eye-to-eye variability was observed with viral
rescue than with pharmacologic rescue. Because of their small
size and relatively large lenses, which occupy about 70% of
the eye, subretinal injection surgery is more complicated for
mouse eyes than it would be for larger eyes.
While direct comparison of rescue methods is difﬁcult, it
appears that both therapeutic methods provide efﬁcient
recovery of higher order visual responses, as tested by PLRs.
The clear advantage of oral retinoid treatment is its ease of
administration compared with the subretinal injections
required for viral vectors. Its primary disadvantage is its
potential for long-term systemic toxicity compared to vector
targeting of LRAT to the RPE. The usual advantage of rAAV-
delivered gene therapy over systemic drugs is the persistence
of passenger gene expression after a single administration;
however, in this case there was a gradual but distinct loss of
delivered LRAT function after several months. This has not
been observed in other systems (RPE65 dog and mouse
studies) and may reﬂect an Lrat
 / -speciﬁc effect on RPE
viability. The slow and gradual decline in ERG amplitude in
treated mice is also observed with age in Lrat
þ/þ mice.
Although the decline rate during the ﬁrst 7 mo of life for
Lrat
þ/þmice is slight (T. Maeda and KP, unpublished data) and
is slower than in rAAV-treated mice, the direct comparison is
not precise, as untreated retinas of Lrat
 /  degenerate slowly,
and the level of opsin expression appears to be slightly lower
(unpublished data). Thus, the observed decline in ERG
amplitudes could be a result of several different factors,
including the stability of rAAV infection, retina remodeling
in Lrat
 /  mice [35], and shorter ROS structure in Lrat
 /  mice
(this study) and degeneration of cone photoreceptors
Figure 6. Light-Induced Pupillary Constriction of Lrat
 /  Mice Before and
After Treatment with 9-cis-R-Ac or rAAV-Lrat
(A–H) 470 nm light (4.79 3 10
13 photons cm
 2 sec
 1) was used to
stimulate pupillary constriction. Untreated Lrat
 /  pupil before (A) and
during (B) light exposure. Same mouse as in (A and B) subsequent to
treatment with 9-cis-R-Ac, before (C) and during (D) light exposure.
Control, untreated pupil of Lrat
 /  mouse before (E) and during (F) light
exposure. Contralateral eye of mouse shown in (E and F) treated with
rAAV-Lrat, before (G) and during (H) light exposure.
(I) Irradiance-response relations for PLR to 470 nm light.
DOI: 10.1371/journal.pmed.0020333.g006
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Recovery of Vision in Blind Mice(unpublished data). Importantly, 9-cis-R-Ac treatment ap-
peared to improve rescue in virally treated animals, and
resulted in reconstitution of both native 11-cis-retinoids and
administered 9-cis-retinoids simultaneously.
Insight into Retinoid Metabolism
The level of 9-cis-RAL is maintained in the eyes of 9-cis-R-
Ac-treated Lrat
 /  dark-adapted mice for over 4 mo. This
ﬁnding suggests that the rod-RPE system efﬁciently recycles
the chromophore of phagocytosed visual pigment. This
phenomenon can be readily observed, because retinoids are
only transiently stored in organs other than the eye in Lrat
 / 
mice. Approximately 10% of the ROS is renewed each day
[46]. The entire length of the ROS is thus completely renewed
in less than 2 wk. However, the 9-cis-RAL based pigment
persists in the eye for 4 mo post-gavage at a ;50% level. This
can be explained only by the recovery of 9-cis-chromophore
from isorhodopsin phagocytosed by the RPE. Second, even
though REs are transiently formed in the eye (Table 1), they
do not support the retinoid cycle, suggesting that LRAT is a
key enzyme in this process and that formation of esters is
insufﬁcient in the completion of the cycle. This observation
suggests that localization of these esters is crucial for the
proper function of the retinoid cycle. Third, we conﬁrmed
reports obtained by Fan et al. [23] that mice with an impaired
retinoid cycle appear to spontaneously generate 9-cis-RAL
that is then trapped by ROS containing almost exclusively
free opsin.
Leber Congenital Amaurosis and Potential Treatment
The major advantage of retinoid-based treatments of LCA
resulting from the deﬁciency of LRAT is that these
compounds are not stored in the liver for any prolonged
time and are quickly oxidized and secreted. Retinoid
absorption in mammals is an active process driven by
esteriﬁcation/hydrolysis cycles in the intestine and liver and
in the RPE. Esteriﬁcation is carried out mainly by LRAT [47],
as evidenced by the fact that the absence of LRAT makes
retinoids vulnerable to quick elimination from the body. In
the absence of LRAT, the equilibrium between ROLs and REs
is clearly shifted in favor of free ROL. Low levels of REs are
present in mice deﬁcient in LRAT expression (Lrat
 / ), but
these esters are formed transiently as a possible consequence
of acyl-CoA:retinol acyltransferase activity [25, 48].
An important ﬁnding is that the pharmacological treat-
ment can be sustained multiple times, and that several low-
dose treatments show cumulative effects. This treatment is
possible at any age, as the morphological structure of the
retina is to some degree preserved in both young and old
mice. These data are reminiscent of results obtained
following gene therapy of RPE65-deﬁcient mice and dogs
[7,9,12,16,49,50].
Cis- and all-trans-RALs are irreversibly oxidized to RAs by
RAL dehydrogenase types 1, 2, 3, and 4 [51]. All-trans-RA and
its 9-cis-isomer are important regulators of gene expression
via nuclear receptors [52]. For any retinoid-based therapy
there can be negative side effects resulting from potential
production of RAs and their teratogenic effects. To prevent
their accumulation, RAs are oxidized by CYP26A1, CYP26B1,
and CYP26C1 to 4-hydroxy-RA, 4-oxo-RA, and 18-hydroxy-
RA [53]. As demonstrated here, only a low and transient level
of RAs is observed in the Lrat
 / mice gavaged with 9-cis-R-Ac,
arguing that the potential side effects due to RA production
are highly attenuated. More toxicological studies are needed
before pharmacological treatment can be proposed for
treatment of similar human conditions. It is possible that a
combination of viral and pharmacological treatment could be
the most efﬁcient means of restoring vision in patients
afﬂicted with LCA, for whom no treatment is currently
available.
The rescue of PLRs in Lrat
 /  demonstrates that treatment
of the retinal defects results in ultimate improvement in
signaling from eye to brain. PLRs are mediated by both inner
retinal, non-visual photoreceptors [54] and rod and cone
input. While measurement of the PLR in this study could not
readily distinguish between rescue of inner and outer retinal
photoreceptors, given the observed dramatic improvement of
the ERG, these results suggest that rescued outer retinal
function may be at least partly responsible for rescue of the
PLR. Determination of the extent to which pharmacologic or
somatic gene therapy rescue of Lrat
 /  mice would allow
restoration of actual visual function will require additional
study. It is unknown at present to what extent mice lacking
Lrat develop normal intraretinal circuitry, and it is similarly
unknown to what extent these mice develop amblyopia from
visual deprivation. The apparent visual improvement asso-
ciated with rAAV rescue in dogs mutant in the Rpe65 gene [9],
however, does suggest that form vision may be restored in at
least some forms of LCA.
Our ﬁndings establish that both chromophore supplemen-
tation and somatic gene therapy are effective in improving
visual functions in the Lrat
 / mouse, an animal model of LCA
that accurately replicates the pathology of the disease. The
treatments are optimally effective in combination and if the
chromophore supplementation is continued at low doses for
a longer period of time. Applying 9-cis-R-Ac treatment to
virally treated animals appeared to improve rescue, and
resulted in reconstitution of both native 11-cis- and admin-
istered 9-cis- retinoids simultaneously. There is a great value
in combined approaches, for several reasons. First, either one
may prove to be more suitable for a speciﬁc age group of
patients, thus offering effective treatment for a wider age
range; second, a partial and regional rescue by rAVV, as
observed in the Rpe65-deﬁcient dog (unpublished data), could
be augmented by retinoid treatment, reaching the whole
retina; third, the rescue in rAVV-treated animals allows
storage of 9-cis-REs that might be mobilized when needed (for
example, high bleaching levels). Clinically, it is likely that
pharmacologic and somatic gene therapeutic approaches, if
successful, could be used in complementary fashion; for
example, treatment of appropriate patients with oral
retinoids could begin in infancy to avoid amblyopia, avoiding
the difﬁculties associated with surgery in very young patients,
while at older ages long-lasting drug-free treatment might be
achieved by surgical introduction of viral vectors.
This work on the rescue of vision extends previous studies
by Van Hooser et al. [7,16] in part by employing novel
compounds with potentially better drug-like properties, and
to the second LCA mouse model. In contrast to Rpe65
 / mice,
Lrat
 / mice do not have signiﬁcant capacity to store retinoids
outside of the visual pigment; however, the pharmacological
approach was highly successful. There have been reports
documenting the potential adverse effects of high doses of
retinoids [55]. During these and related studies of both acute
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adverse effects were observed for mice of several genetic
backgrounds. Number and size of litters, coat grooming,
survival after gavage, post-natal development, and growth/
weight curves were unaffected by treatment. Lrat
 /  mice may
be particularly resistant to potential toxicity of RE com-
pounds, as lack of esteriﬁcation of the retinoid agents actively
leads to rapid removal through secretion and oxidation to
oxo/hydroxo RA compounds. This reaction occurs not only in
the eye but also in the liver, where LRAT is also normally
expressed. The transient formation and accumulation of
retinoids observed in these mice soon after treatment
disappeared within a day in most cases. Only visual pigments
had the capability to retain these retinoids for a long period
of time, as shown in Figure 2H. These observations raise the
hope that, after formal toxicological studies, these RE pro-
drugs have the potential to be extended effectively to
humans.
Supporting Information
Figure S1. Chromatographic Separation of Retinoids Extracted from
16 Lrat
 /  Mouse Eyes
(A) Peak 1, syn-11-cis-RAL oxime; 2, undetermined compound with
kmax at 315 nm; 3, syn-all-trans-RAL oxime; 4, syn-9-cis-RAL oxime; 5,
13-cis-ROL; and 6, all-trans-ROL.
(B) Retinoids bound to immunoafﬁnity puriﬁed opsin from 40
untreated Lrat
 /  mouse eyes (one-third of the sample was loaded on
the HPLC column).
Found at DOI: 10.1371/journal.pmed.0020333.sg001 (125 KB PDF).
Figure S2. Levels of 9-cis-RAL in Mice of Different Ages Treated with
9-cis-R-Ac
(A) 9-cis-RAL oxime levels in Lrat
 / mouse eyes following gavage with
20 lmol 9-cis-R-Ac at differing ages. The analysis is performed after
72 h of post-gavage dark adaptation (n   3).
(B) ROS thickness as a function of the retinal location from the optic
nerve head (in mm). Four age-matched retinas of WT and Lrat
 / were
analyzed both in inferior/superior and nasal/temporal orientations,
and the data plotted with Microsoft Excel. The dotted lines represent
data from 2-mo-old Lrat
þ/  and Lrat
 /  mice as published earlier [10].
Found at DOI: 10.1371/journal.pmed.0020333.sg002 (60 KB PDF).
Figure S3. Retinoid Analysis and ERG of rAAV-Lrat Treated Lrat
 / 
Mice Augmented with 9-cis-R-Ac
(A) Lrat
 /  mouse treated with rAAV-Lrat. Inset, immunoafﬁnity-
puriﬁed rhodopsin from the retina of Lrat
 / mice treated with rAAV-
Lrat virus. E, corresponding fraction in elution.
(B) Lrat
 /  mouse treated with 9-cis-R-Ac.
(C) Lrat
 /  mouse treated with rAAV-Lrat and 9-cis-R-Ac. Peaks
marked * represent the solvent change artifact. Inset, the chromato-
gram of retinoids from WT mouse.
(D) Scotopic single-ﬂash ERG a-waves.
(E) Scotopic single-ﬂash ERG b-waves (n   10, data shown with SEM).
Found at DOI: 10.1371/journal.pmed.0020333.sg003 (175 KB PDF).
Figure S4. Scatter Plot of a- and b-waves of ERGs Obtained from
rAAV-Lrat-Treated and Control Lrat
 /  Mice
(A) ERG a-waves of 6- to 7-wk-old Lrat
 /  control mice.
(B) ERG b-waves of 6- to 7- wk-old Lrat
 /  control mice.
(C) ERG a-waves of 6- to 7- wk-old rAAV-Lrat-treated mice.
(D) ERG b-waves of 6- to 7- wk-old rAAV-Lrat-treated mice (n   39).
Found at DOI: 10.1371/journal.pmed.0020333.sg004 (129 KB PDF).
Video S1. Effect of 9-cis-R-Ac Treatment on the PLR of Lrat
 /  Mice
PLRs of an individual Lrat
 / mouse (left eye) recorded prior (control)
and 72 h subsequent (9-cis-R-Ac) to three 5-lmol doses of 9-cis-R-Ac.
Presence of light stimulus (30-s pulse of narrow bandpass 470 nm
light, 1.38310
14 photons cm
 2 sec
 1) is represented in the movie by a
light bulb symbol.
Found at DOI: 10.1371/journal.pmed.0020333.sv001 (3.0 MB MOV).
Video S2. Effect of Intraocular Injection of rAAV-Lrat on the PLR of
Lrat
 /  Mice
PLRs of an individual Lrat
 / mouse recorded from rAAV-Lrat-treated
left eye (rAAV-Lrat) and non-treated right eye (control). Presence of
light stimulus (30-s pulse of narrow bandpass 470 nm light, 4.79310
13
photons cm
 2 sec
 1) is represented in the movie by a light bulb
symbol.
Found at DOI: 10.1371/journal.pmed.0020333.sv002 (3.0 MB MOV).
Accession Number
The GenBank (http://www.ncbi.nlm.nih.gov/) accession number of
Chromosome 11q13 is AF139813.
Acknowledgments
We thank Dan Possin for EM analysis and Rebecca Birdsong for
comments on the manuscript. This research was supported by
National Institutes of Health grants EY09339 to KP, EY08123 to
WB, EY14988 to RNVG, and EY11123 and EY13729 to WWH; grants
from Research to Prevent Blindness to the Department of Oph-
thalmology at the University of Utah and Washington University; the
Culpepper Medical Scholar grant from Rockefeller Brothers Foun-
dation to RNVG; a Center Grant from the Foundation Fighting
Blindness to the University of Utah; and a grant from the EK Bishop
Foundation. Dan Possin was supported by a Vision CORE Grant
EY01730. Retinagenix had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
References
1. Rattner A, Sun H, Nathans J (1999) Molecular genetics of human retinal
disease. Annu Rev Genet 33: 89–131.
2. Baehr W, Wu SM, Bird AC, Palczewski K (2003) The retinoid cycle and
retina disease. Vision Res 43: 2957–2958.
3. Jacobson SG, Cideciyan AV, Regunath G, Rodriguez FJ, Vandenburgh K, et
al. (1995) Night blindness in Sorsby’s fundus dystrophy reversed by vitamin
A. Nat Genet 11: 27–32.
4. Lotery AJ, Namperumalsamy P, Jacobson SG, Weleber RG, Fishman GA, et
al. (2000) Mutation analysis of 3 genes in patients with Leber congenital
amaurosis. Arch Ophthalmol 118: 538–543.
5. Cremers FP, van den Hurk JA, den Hollander AI (2002) Molecular genetics
of Leber congenital amaurosis. Hum Mol Genet 11: 1169–1176.
6. Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, et al. (1998) Rpe65 is
necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat
Genet 20: 344–351.
7. Van Hooser JP, Aleman TS, He YG, Cideciyan AV, Kuksa V, et al. (2000)
Rapid restoration of visual pigment and function with oral retinoid in a
mouse model of childhood blindness. Proc Natl Acad Sci U S A 97: 8623–
8628.
8. Campochiaro PA (2002) Gene therapy for retinal and choroidal diseases.
Expert Opin Biol Ther 2: 537–544.
9. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, et al. (2001) Gene
therapy restores vision in a canine model of childhood blindness. Nat
Genet 28: 92–95.
10. Batten ML, Imanishi Y, Maeda T, Tu DC, Moise AR, et al. (2004) Lecithin-
retinol acyltransferase is essential for accumulation of all-trans-retinyl
esters in the eye and in the liver. J Biol Chem 279: 10422–10432.
11. Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, et al. (2001)
Mutations in the gene encoding lecithin retinol acyltransferase are
associated with early-onset severe retinal dystrophy. Nat Genet 28: 123–
124.
12. Imanishi Y, Batten ML, Piston DW, Baehr W, Palczewski K (2004)
Noninvasive two-photon imaging reveals retinyl ester storage structures
in the eye. J Cell Biol 164: 373–383.
13. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N (1996) A
‘‘humanized’’ green ﬂuorescent protein cDNA adapted for high-level
expression in mammalian cells. J Virol 70: 4646–4654.
14. Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ (2004) Analysis of the
VMD2 promoter and implication of E-box binding factors in its regulation.
J Biol Chem 279: 19064–19073.
15. Maeda T, Van Hooser JP, Driessen CA, Filipek S, Janssen JJ, et al. (2003)
Evaluation of the role of the retinal G protein-coupled receptor (RGR) in
the vertebrate retina in vivo. J Neurochem 85: 944–956.
16. Van Hooser JP, Liang Y, Maeda T, Kuksa V, Jang GF, et al. (2002) Recovery
of visual functions in a mouse model of Leber congenital amaurosis. J Biol
Chem 277: 19173–19182.
17. Palczewski K, Van Hooser JP, Garwin GG, Chen J, Liou GI, et al. (1999)
Kinetics of visual pigment regeneration in excised mouse eyes and in mice
with a targeted disruption of the gene encoding interphotoreceptor
retinoid-binding protein or arrestin. Biochemistry 38: 12012–12019.
18. Zhu L, Jang GF, Jastrzebska B, Filipek S, Pearce-Kelling SE, et al. (2004) A
PLoS Medicine | www.plosmedicine.org November 2005 | Volume 2 | Issue 11 | e333 1188
Recovery of Vision in Blind Micenaturally occurring mutation of the opsin gene (T4R) in dogs affects
glycosylation and stability of the G protein-coupled receptor. J Biol Chem
279: 53828–53839.
19. Sampath AP, Rieke F (2004) Selective transmission of single photon
responses by saturation at the rod-to-rod bipolar synapse. Neuron 41: 431–
443.
20. Kane MA, Chen N, Sparks S, Napoli JL (2005) Quantiﬁcation of endogenous
retinoic acid in limited biological samples by LC/MS/MS. Biochem J 388:
363–369.
21. Klvanova J, Brtko J (2002) Selected retinoids: Determination by isocratic
normal-phase HPLC. Endocr Regul 36: 133–141.
22. Haeseleer F, Jang GF, Imanishi Y, Driessen CA, Matsumura M, et al. (2002)
Dual-substrate speciﬁcity short chain retinol dehydrogenases from the
vertebrate retina. J Biol Chem 277: 45537–45546.
23. Fan J, Rohrer B, Moiseyev G, Ma JX, Crouch RK (2003) Isorhodopsin rather
than rhodopsin mediates rod function in RPE65 knock-out mice. Proc Natl
Acad Sci U S A 100: 13662–13667.
24. Bok D (1985) Retinal photoreceptor-pigment epithelium interactions.
Friedenwald lecture. Invest Ophthalmol Vis Sci 26: 1659–1694.
25. Yen CL, Monetti M, Burri BJ, Farese RV Jr. (2005) The triacylglycerol
synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols,
waxes, and retinyl esters. J Lipid Res 46: 1502–1511.
26. Dowling JE (1960) Chemistry of visual adaptation in the rat. Nature 188:
114–118.
27. Palczewski K, Saari JC (1997) Activation and inactivation steps in the visual
transduction pathway. Curr Opin Neurobiol 7: 500–504.
28. Woodruff ML, Wang Z, Chung HY, Redmond TM, Fain GL, et al. (2003)
Spontaneous activity of opsin apoprotein is a cause of Leber congenital
amaurosis. Nat Genet 35: 158–164.
29. Saari JC, Garwin GG, Van Hooser JP, Palczewski K (1998) Reduction of all-
trans-retinal limits regeneration of visual pigment in mice. Vision Res 38:
1325–1333.
30. Fu Y, Zhong H, Wang M-HH, Luo D-G, Liao HW, et al. (2005) Intrinsically
photosensitive retinal ganglion cells detect light with a vitamin A-based
photopigment, melanopsin. Proc Natl Acad Sci U S A 102: 10339–10344
31. Frasson M, Sahel JA, Fabre M, Simonutti M, Dreyfus H, et al. (1999) Retinitis
pigmentosa: Rod photoreceptor rescue by a calcium-channel blocker in the
rd mouse. Nat Med 5: 1183–1187.
32. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, et al.
(1998) Protection of mouse photoreceptors by survival factors in retinal
degenerations. Invest Ophthalmol Vis Sci 39: 592–602.
33. Okoye G, Zimmer J, Sung J, Gehlbach P, Deering T, et al. (2003) Increased
expression of brain-derived neurotrophic factor preserves retinal function
and slows cell death from rhodopsin mutation or oxidative damage. J
Neurosci 23: 4164–4172.
34. Li T, Sandberg MA, Pawlyk BS, Rosner B, Hayes KC, et al. (1998) Effect of
vitamin A supplementation on rhodopsin mutants threonine-17 –.
methionine and proline-347 –. serine in transgenic mice and in cell
cultures. Proc Natl Acad Sci U S A 95: 11933–11938.
35. Jones BW, Watt CB, Frederick JM, Baehr W, Chen CK, et al. (2003) Retinal
remodeling triggered by photoreceptor degenerations. J Comp Neurol 464:
1–16.
36. Penn JS, Williams TP (1986) Photostasis: Regulation of daily photon-catch
by rat retinas in response to various cyclic illuminances. Exp Eye Res 43:
915–928.
37. Hofmann KP, Schleicher A, Emeis D, Reichert J (1981) Light-induced axial
and radial shrinkage effects and changes of the refractive index in isolated
bovine rod outer segments and disc vesicles: Physical analysis of near-
infrared scattering changes. Biophys Struct Mech 8: 67–93.
38. Naash MI, LaVail MM, Anderson RE (1989) Factors affecting the
susceptibility of the retina to light damage. Prog Clin Biol Res 314: 513–522.
39. Znoiko SL, Rohrer B, Lu K, Lohr HR, Crouch RK, et al. (2005)
Downregulation of cone-speciﬁc gene expression and degeneration of
cone photoreceptors in the rpe65
 / mouse at early ages. Invest Ophthalmol
Vis Sci 46: 1473–1479.
40. Baylor DA (1987) Photoreceptor signals and vision. Proctor lecture. Invest
Ophthalmol Vis Sci 28: 34–49.
41. McBee JK, Palczewski K, Baehr W, Pepperberg DR (2001) Confronting
complexity: The interlink of phototransduction and retinoid metabolism
in the vertebrate retina. Prog Retin Eye Res 20: 469–529.
42. Imanishi Y, Gerke V, Palczewski K (2004) Retinosomes: New insights into
intracellular managing of hydrophobic substances in lipid bodies. J Cell
Biol 166: 447–453.
43. Vogel S, Piantedosi R, O’Byrne SM, Kako Y, Quadro L, et al. (2002) Retinol-
binding protein-deﬁcient mice: Biochemical basis for impaired vision.
Biochemistry 41: 15360–15368.
44. Harrison EH (2005) Mechanisms of digestion and absorption of dietary
vitamin A. Annu Rev Nutr. 25: 87–103.
45. Kline K, Yu W, Sanders BG (2004) Vitamin E and breast cancer. J Nutr 134:
3458S–3462S.
46. LaVail MM (1976) Rod outer segment disk shedding in rat retina:
Relationship to cyclic lighting. Science 194: 1071–1074.
47. Ruiz A, Winston A, Lim YH, Gilbert BA, Rando RR, et al. (1999) Molecular
and biochemical characterization of lecithin retinol acyltransferase. J Biol
Chem 274: 3834–3841.
48. O’Byrne SM, Wongsiriroj N, Libien JM, Vogel S, Goldberg IJ, et al. (2005)
Retinoid absorption and storage is impaired in mice lacking lecithin:
Retinol acyltransferase (LRAT). J Biol Chem. E-pub ahead of print.
49. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, et al. (2003)
Organization of the G protein-coupled receptors rhodopsin and opsin in
native membranes. J Biol Chem 278: 21655–21662.
50. Aleman TS, Jacobson SG, Chico JD, Scott ML, Cheung AY, et al. (2004)
Impairment of the transient pupillary light reﬂex in Rpe65
 /  mice and
humans with Leber congenital amaurosis. Invest Ophthalmol Vis Sci 45:
1259–1271.
51. Zhao D, McCaffery P, Ivins KJ, Neve RL, Hogan P, et al. (1996) Molecular
identiﬁcation of a major retinoic-acid-synthesizing enzyme, a retinalde-
hyde-speciﬁc dehydrogenase. Eur J Biochem 240: 15–22.
52. Chambon P (1996) A decade of molecular biology of retinoic acid
receptors. Faseb J 10: 940–954.
53. Fujii H, Sato T, Kaneko S, Gotoh O, Fujii-Kuriyama Y, et al. (1997)
Metabolic inactivation of retinoic acid by a novel P450 differentially
expressed in developing mouse embryos. EMBO J 16: 4163–4173.
54. Berson DM (2003) Strange vision: Ganglion cells as circadian photo-
receptors. Trends Neurosci 26: 314–320.
55. Collins, M.D. and Mao, G.E. (1999) Teratology of retinoids. Annu Rev
Pharmacol Toxicol 39, 399–430
Patient Summary
Background Some causes of blindness are inherited. Leber congenital
amaurosis is one inherited disease that causes degeneration and loss of
activity of the retina—the tissue at the back of the eye. Hence, babies
have a severe loss of vision at birth as well as roving eye movements
(nystagmus), deep-set eyes, and sensitivity to bright light. One cause of
Leber congenital amaurosis is loss of an enzyme called lecithin:retinol
acyl transferase (LRAT), which is required for regeneration of a pigment
necessary for the eye to detect light. Currently there is no treatment for
this condition.
Why Was This Study Done? There are animal models of this disease,
and previous work has suggested that there are two possible ways of
treating this condition. One is by giving by mouth synthetic pigments
similar to those in the eye. Another is by gene therapy with viruses that
replace the abnormal gene with normal copies. The authors wanted to
test these methods in a mouse model, and see if the two approaches
worked well together.
What Did the Researchers Do and Find? They treated mice that had a
genetic defect mimicking the human condition by placing a virus
carrying the normal gene directly into their eyes. They also gave the mice
pro-drugs (compounds that are turned into the active drug inside the
body) by mouth, which bypassed the missing step in the regeneration of
the retinal compound. The authors found that they got the best results
either using individual methods or when they tried both approaches
together. They could show that the mice had the electrical impulses that
are a sign that the eye is working correctly, and in addition, their pupils
responded to light.
What Do These Findings Mean? These results are an early step to
making these treatments available to patients. Obviously, they would
only help patients who had this particular genetic defect, and possible
defects in genes from this same metabolic pathway. Before these
treatments were to be used, many other questions would need to be
answered, including whether these oral compounds might be toxic if
given repeatedly—as they would need to be. Also, acceptable methods
of placing the gene therapy into human eyes would need to be found.
Where Can I Get More Information Online? The Foundation Fighting
Blindness funds research on retinal degenerative diseases, and has a
number of pages of information for patients and families:
http://www.blindness.org/
Contact a Family is a UK charity that has information on specific
conditions and rare disorders:
http://www.cafamily.org.uk
MedlinePlus also has a series of pages on retinal disorders:
http://www.nlm.nih.gov/medlineplus/retinaldisorders.html
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